JP2023100828A5 - - Google Patents

Download PDF

Info

Publication number
JP2023100828A5
JP2023100828A5 JP2023076182A JP2023076182A JP2023100828A5 JP 2023100828 A5 JP2023100828 A5 JP 2023100828A5 JP 2023076182 A JP2023076182 A JP 2023076182A JP 2023076182 A JP2023076182 A JP 2023076182A JP 2023100828 A5 JP2023100828 A5 JP 2023100828A5
Authority
JP
Japan
Prior art keywords
cells
population
dna template
primary human
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023076182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023100828A (ja
Filing date
Publication date
Priority claimed from JP2019569305A external-priority patent/JP7275054B2/ja
Application filed filed Critical
Publication of JP2023100828A publication Critical patent/JP2023100828A/ja
Publication of JP2023100828A5 publication Critical patent/JP2023100828A5/ja
Priority to JP2025031513A priority Critical patent/JP2025078701A/ja
Pending legal-status Critical Current

Links

JP2023076182A 2017-06-15 2023-05-02 標的化された非ウイルスdna挿入 Pending JP2023100828A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031513A JP2025078701A (ja) 2017-06-15 2025-02-28 標的化された非ウイルスdna挿入

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520117P 2017-06-15 2017-06-15
US62/520,117 2017-06-15
US201762552180P 2017-08-30 2017-08-30
US62/552,180 2017-08-30
JP2019569305A JP7275054B2 (ja) 2017-06-15 2018-06-15 標的化された非ウイルスdna挿入

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019569305A Division JP7275054B2 (ja) 2017-06-15 2018-06-15 標的化された非ウイルスdna挿入

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031513A Division JP2025078701A (ja) 2017-06-15 2025-02-28 標的化された非ウイルスdna挿入

Publications (2)

Publication Number Publication Date
JP2023100828A JP2023100828A (ja) 2023-07-19
JP2023100828A5 true JP2023100828A5 (cg-RX-API-DMAC7.html) 2024-04-03

Family

ID=64659467

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019569305A Active JP7275054B2 (ja) 2017-06-15 2018-06-15 標的化された非ウイルスdna挿入
JP2023076182A Pending JP2023100828A (ja) 2017-06-15 2023-05-02 標的化された非ウイルスdna挿入
JP2025031513A Pending JP2025078701A (ja) 2017-06-15 2025-02-28 標的化された非ウイルスdna挿入

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019569305A Active JP7275054B2 (ja) 2017-06-15 2018-06-15 標的化された非ウイルスdna挿入

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031513A Pending JP2025078701A (ja) 2017-06-15 2025-02-28 標的化された非ウイルスdna挿入

Country Status (13)

Country Link
US (5) US20200362355A1 (cg-RX-API-DMAC7.html)
EP (1) EP3638317A4 (cg-RX-API-DMAC7.html)
JP (3) JP7275054B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240027153A (cg-RX-API-DMAC7.html)
CN (2) CN118599915A (cg-RX-API-DMAC7.html)
AU (2) AU2018283405B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019026625A2 (cg-RX-API-DMAC7.html)
CA (1) CA3067382A1 (cg-RX-API-DMAC7.html)
IL (1) IL271389B2 (cg-RX-API-DMAC7.html)
MX (3) MX2019015188A (cg-RX-API-DMAC7.html)
MY (1) MY200418A (cg-RX-API-DMAC7.html)
SG (1) SG11201912179SA (cg-RX-API-DMAC7.html)
WO (1) WO2018232356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
US12492411B2 (en) 2018-05-30 2025-12-09 The Regents Of The University Of California Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA)
EP3938510A1 (en) * 2019-03-11 2022-01-19 Sorrento Therapeutics, Inc. Improved process for integration of dna constructs using rna-guided endonucleases
CN114107292B (zh) * 2020-08-27 2024-03-12 阿思科力(苏州)生物科技有限公司 用于外源基因定点插入的基因编辑系统和方法
WO2022047003A1 (en) * 2020-08-27 2022-03-03 Tmunity Therapeutics Inc. Vector-free process for manufacture of engineered immune cells
CN113046381A (zh) * 2021-04-12 2021-06-29 南华大学 用于分离生物体内特异性蛋白-dna复合体的方法、融合蛋白及其制备方法
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
EP4522182A4 (en) * 2022-05-10 2026-05-06 Editas Medicine Inc GENOME EDITING OF CELLS
US20250297288A1 (en) * 2022-05-10 2025-09-25 Editas Medicine, Inc. Genome editing of b cells
CR20250095A (es) 2022-09-13 2025-09-01 Arsenal Biosciences Inc Células inmunitarias que coexpresan arnhc de tgfbr
JP2025532585A (ja) 2022-09-16 2025-10-01 アーセナル バイオサイエンシズ インコーポレイテッド 組み合わせ遺伝子摂動を有する免疫細胞
US20260232734A1 (en) 2023-02-27 2026-08-13 Adaptive Biotechnologies Corporation Therapeutic T-Cell Receptors Targeting KRAS G12D
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
EP4680748A1 (en) 2023-03-13 2026-01-21 Arsenal Biosciences, Inc. Synthetic pathway activators
MX2025014893A (es) * 2023-06-14 2026-02-03 Arsenal Biosciences Inc Ingenieria de celulas no virales
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
TW202544044A (zh) 2024-03-20 2025-11-16 美商亞森諾生物科學公司 靶向slc34a2及tmprss4之系統及其使用方法
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2026136848A2 (en) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Cd70-targeted cars and engineered cells comprising same and related methods
WO2026151965A1 (en) 2025-01-10 2026-07-16 Arsenal Biosciences, Inc. Shrna targeting fas and tgfbrii genes

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2003531616A (ja) 2000-04-28 2003-10-28 サンガモ バイオサイエンシーズ, インコーポレイテッド 細胞性クロマチンに外因性分子を結合させるための方法
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
JP4070611B2 (ja) 2001-04-23 2008-04-02 アマクサ アーゲー 電気穿孔法用の緩衝溶液およびその使用を含む方法
DK2574662T3 (da) 2001-08-22 2021-09-20 Maxcyte Inc Fremgangsmåde til elektroporation af biologiske prøver
US20050136040A1 (en) 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
ITMI20030821A1 (it) 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
CN1836048A (zh) 2003-06-10 2006-09-20 图尔金株式会社 可转导的dna结合蛋白
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE502004009820D1 (de) 2004-03-15 2009-09-10 Lonza Cologne Ag Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
WO2005113820A2 (en) 2004-05-12 2005-12-01 Maxcyte, Inc. Methods and devices related to a regulated flow electroporation chamber
RU2006143560A (ru) 2004-06-12 2008-07-20 Диджитал Био Технолоджи Ко Устройство для электропорации с удлиненным полым элементом
ES2465467T3 (es) 2004-06-14 2014-06-05 Lonza Cologne Ag Procedimiento y disposición de circuito para el tratamiento de material biológico
WO2005123962A2 (en) 2004-06-14 2005-12-29 The University Of Texas At Austin Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
JP2008521437A (ja) 2004-11-30 2008-06-26 マックスサイト インコーポレーティッド コンピュータ化されたエレクトロポレーション
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP2325332B1 (en) 2005-08-26 2012-10-31 DuPont Nutrition Biosciences ApS Use of CRISPR associated genes (CAS)
JP2010500029A (ja) 2006-08-11 2010-01-07 ダウ アグロサイエンシィズ エルエルシー ジンクフィンガーヌクレアーゼ媒介相同組換え
JP5779090B2 (ja) 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達
EP2310500B1 (en) 2008-07-18 2015-03-11 Maxcyte, Inc. Methods for optimizing electroporation
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
US8876458B2 (en) 2011-01-25 2014-11-04 United Technologies Corporation Blade outer air seal assembly and support
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US20130236504A1 (en) 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
KR20140101203A (ko) 2013-02-08 2014-08-19 이정민 자동 버핑장치
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN105121650A (zh) 2013-04-02 2015-12-02 拜尔作物科学公司 真核生物中的靶向基因组工程
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
EP3058072B1 (en) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9951353B2 (en) 2013-11-15 2018-04-24 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Engineering neural stem cells using homologous recombination
US10787684B2 (en) * 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
KR20160097338A (ko) * 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도
JP2016539653A (ja) 2013-12-13 2016-12-22 セレクティス 微小藻類のゲノム操作のためのCas9ヌクレアーゼプラットフォーム
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
WO2015115903A1 (en) 2014-02-03 2015-08-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Site-specific dna break-induced genome editing using engineered nucleases
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
CN106536721B (zh) 2014-08-06 2020-12-04 车医科学大学校产学协力团 核酸酶介导的编辑编码hla的基因所产生的免疫相容性细胞
WO2016036754A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
CN113930455A (zh) 2014-10-09 2022-01-14 生命技术公司 Crispr寡核苷酸和基因剪辑
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
EP3247328B1 (en) 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
US20190388469A1 (en) 2015-01-30 2019-12-26 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
US12129471B2 (en) 2015-02-23 2024-10-29 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of human genetic diseases including hemoglobinopathies
WO2016172359A2 (en) 2015-04-24 2016-10-27 The Regents Of The University Of California Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
EP3310932B1 (en) 2015-06-17 2023-08-30 The UAB Research Foundation Crispr/cas9 complex for genomic editing
US11555207B2 (en) * 2015-06-17 2023-01-17 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017035659A1 (en) 2015-09-01 2017-03-09 The Hospital For Sick Children Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
WO2017070169A1 (en) 2015-10-19 2017-04-27 The Methodist Hospital Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
US20180312873A1 (en) 2015-10-20 2018-11-01 10X Genomics, Inc. Method and systems for high throughput single cell genetic manipulation
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
AU2016359629B2 (en) 2015-11-23 2023-03-09 Ranjan BATRA Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
EP3397760A2 (en) 2015-12-30 2018-11-07 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
US20190241910A1 (en) 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
AU2017248259A1 (en) 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
KR102614675B1 (ko) 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
WO2017189336A1 (en) 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
EP3448995A1 (en) * 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
KR102370675B1 (ko) 2016-04-29 2022-03-04 바스프 플랜트 사이언스 컴퍼니 게엠베하 표적 핵산의 변형을 위한 개선된 방법
WO2017210334A1 (en) 2016-05-31 2017-12-07 Massachusetts Institute Of Technology Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform
US11713458B2 (en) 2016-06-20 2023-08-01 Octapharma Ag Means and methods for modifying multiple alleles
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018039084A1 (en) 2016-08-20 2018-03-01 The Regents Of The University Of California High-throughput system and method for the temporary permeablization of cells
JP6837879B2 (ja) 2016-08-26 2021-03-03 日東電工株式会社 粘着テープ
AU2017341736B2 (en) 2016-10-12 2022-09-08 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
AU2017362513A1 (en) 2016-11-18 2019-05-16 Christopher Bradley Massively multiplexed homologous template repair for whole-genome replacement
RU2019121801A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
CN110546495B (zh) 2016-12-30 2022-11-01 加利福尼亚州立大学董事会 用于基因组编辑t细胞的选择和传代的方法
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
EP3703712A4 (en) 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES

Similar Documents

Publication Publication Date Title
Barouch et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
JP6913032B2 (ja) 共通ネオ抗原
JP2024081777A5 (cg-RX-API-DMAC7.html)
Johansson et al. Intradermal electroporation of naked replicon RNA elicits strong immune responses
Daemen et al. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7
JP2024520528A5 (cg-RX-API-DMAC7.html)
JP2018522072A5 (cg-RX-API-DMAC7.html)
Sharpe et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity
Ferrantelli et al. DNA vectors generating engineered exosomes potential CTL vaccine candidates against AIDS, hepatitis B, and tumors
JP2020524998A5 (cg-RX-API-DMAC7.html)
JP2004510440A (ja) 高発現可能遺伝子
JP2023543137A5 (cg-RX-API-DMAC7.html)
JP2019531745A (ja) 主要組織適合遺伝子複合体e分子によって拘束されるt細胞を誘発するサイトメガロウイルスベクター
CN108474003A (zh) 包含微小rna识别元件的cmv载体
JP2008056679A5 (cg-RX-API-DMAC7.html)
EA003554B1 (ru) Фармацевтическая композиция для генерации противовирусного иммунного ответа у человека и животного
Williamson et al. Justification for the inclusion of Gag in HIV vaccine candidates
Rahman et al. An immunoinformatics prediction of novel multi-epitope vaccines candidate against surface antigens of Nipah virus
Zhu et al. Design and evaluation of a multi-epitope DNA vaccine against HPV16
Silins et al. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
JP2024534189A5 (cg-RX-API-DMAC7.html)
Wong et al. Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination
US10533204B2 (en) Method for amplifying a T cell receptor (TCR) cDNA
Genescà et al. Use of nonhuman primate models to develop mucosal AIDS vaccines
Überla Efficacy of AIDS vaccine strategies in nonhuman primates